Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip JERUSALEM & TARRYTOWN, N.Y.-- --Aug. 16, 2018-- Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. today announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis of the knee or hip. At the week 16 primary efficacy analysis, the study met both co-primary endpoints and all key secondary endpoints.
https://www.drugs.com/clinical_trials/teva-regeneron-announce-positive-topline-phase-3-fasinumab-results-patients-chronic-pain-17895.html?
No comments:
Post a Comment